Clinical Trial: NCT02721732
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | M.D. Anderson Cancer Center |
| Information Provided By: | M.D. Anderson Cancer Center |
| Last Update Posted: | 2026-07-17 |
Study Overview
Brief Summary
This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body. Monoclonal antibodies, such as pembrolizumab, may block specific proteins found on white blood cells which may strengthen the immune system and control tumor growth.
Official Title
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors
Conditions
Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Solid Neoplasm, Metastatic Paraganglioma, Metastatic Penile Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Small Cell Carcinoma, Stage III Adrenal Cortex Carcinoma AJCC v7, Stage IV Adrenal Cortex Carcinoma AJCC v7, Stage IV Penile Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Solid Neoplasm, Vascular Neoplasm
Intervention / Treatment
- Other: Laboratory Biomarker Analysis
- Biological: Pembrolizumab
- Other: Questionnaire Administration
Other Study ID Numbers
- 2015-0948
- NCI-2016-00545
- 2015-0948
Start Date (Actual)
2016-08-15
Primary Completion Date (Estimated)
2028-12-31
Study Completion Date (Estimated)
2028-12-31
Enrollment (Actual)
157
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | M.D. Anderson Cancer Center |
| Information Provided By: | M.D. Anderson Cancer Center |
| Last Update Posted: | 2026-07-17 |
Study Overview
Brief Summary
This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body. Monoclonal antibodies, such as pembrolizumab, may block specific proteins found on white blood cells which may strengthen the immune system and control tumor growth.
Official Title
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors
Conditions
Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Germ Cell Tumor, Metastatic Malignant Solid Neoplasm, Metastatic Paraganglioma, Metastatic Penile Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Small Cell Carcinoma, Stage III Adrenal Cortex Carcinoma AJCC v7, Stage IV Adrenal Cortex Carcinoma AJCC v7, Stage IV Penile Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Solid Neoplasm, Vascular Neoplasm
Intervention / Treatment
- Other: Laboratory Biomarker Analysis
- Biological: Pembrolizumab
- Other: Questionnaire Administration
Other Study ID Numbers
- 2015-0948
- NCI-2016-00545
- 2015-0948
Start Date (Actual)
2016-08-15
Primary Completion Date (Estimated)
2028-12-31
Study Completion Date (Estimated)
2028-12-31
Enrollment (Actual)
157
Study Type
Interventional
Phase
Phase 2